Advanced Non-clear Cell Renal Cell Carcinoma Clinical Trial
— ASPENOfficial title:
A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)
| Verified date | September 2017 |
| Source | Duke University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
| Status | Completed |
| Enrollment | 131 |
| Est. completion date | April 2015 |
| Est. primary completion date | February 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Histologically confirmed advanced Renal Cell Carcinoma (RCC), with non-clear cell pathology. 2. RCC tumor tissue available for correlative sciences, from either primary or metastatic site or both. 3. At the time of screening, at least 4 weeks since prior palliative radiation therapy and/or major surgery, and resolution of all toxic effects of prior therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; version 4.0) Grade 1. 4. Subject must have radiographic evidence of metastatic disease with at least 1 measurable per RECIST 1.1 criteria (Attachment 1)]. 5. Age > 18 years. 6. Adequate laboratory values 7. Karnofsky Performance Status = 60 (Attachment 2). 8. Life expectancy of at least 3 months. 9. Written, signed, dated, and witnessed Institutional Review Board (IRB) or Institutional Ethics Committee (IEC) approved informed consent form (ICF) before any screening procedures are performed. Exclusion Criteria: 1. Subjects with a history of or active central nervous system (CNS) metastases. 2. Prior systemic therapy for RCC, including mTOR and anti-angiogenic therapy, chemotherapy, biologic or experimental therapy. 3. Subjects with collecting duct, medullary, small cell, oncocytoma, or lymphoma-type pathology. 4. Subjects receiving known strong CYP3A4 isoenzyme inhibitors and/or inducers. 5. Major surgery, open biopsy, traumatic injury, or radiotherapy within 4 weeks of the screening visit. 6. Subjects who have not recovered from prior biopsy, surgery, traumatic injury, and/or radiation therapy. 7. Presence of a non-healing wound or ulcer. 8. Grade 3 hemorrhage within the past month. 9. Hypertension with systolic blood pressure of >180 mm Hg and/or diastolic pressure >100 mm Hg. 10. Subjects with American Heart Association (AHA) Class 2-4 heart disease or any history of congestive heart failure with an ejection fraction <50%, or history of unstable angina, myocardial infarction, coronary artery bypass graft, cerebrovascular accident, transient ischemic attack, or pulmonary embolism within 6 months of entry. 11. Diabetes mellitus with glycosylated hemoglobin A1c (HbgA1c) > 10% despite therapy. 12. A history of interstitial pneumonitis. 13. Subjects with active autoimmune disorder(s) being treated with immunosuppressive agents within 4 weeks prior to the screening visit. 14. Subjects receiving immunosuppressive agents and those with chronic viral/bacterial/fungal illnesses such as human immunodeficiency virus (HIV). 15. Patients who have receive immunization with attenuated live vaccines within one week of study entry or during study period. 16. Patients with active infection(s), active antimicrobial therapy or serious intercurrent illness. 17. History of other prior malignancy in past 5 years. 18. Pregnant or nursing women. 19. Major medical/psychiatric illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study, including inability to absorb oral medications and history of noncompliance to medical regimens. 20. Known hypersensitivity to any of the components in everolimus or sunitinib product 21. Subjects taking agents that significantly prolong the QTc interval are not eligible. 22. Proteinuria with a spot urine protein/creatinine ratio >2 or 24 hour urine protein >2 grams per 24 hours. 23. Severely impaired lung function as defined as spirometry and Carbon Monoxide Diffusing Capacity (DLCO) that is 50% of the normal predicted value and/or O2 saturation that is 88% or less at rest on room air. 24. Advanced liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C). |
| Country | Name | City | State |
|---|---|---|---|
| Canada | London Health Sciences Center | London | Ontario |
| Canada | BC Cancer Agency | Vancouver | British Columbia |
| Canada | CancerCare Manitoba, Med Onc, Dept Hem and Onc | Winnipeg | Manitoba |
| United Kingdom | Cambridge Cancer Trials Centre | Cambridge | England |
| United Kingdom | Beatson West Scotland Cancer Centre | Glasgow | Scottland |
| United Kingdom | Churchill Hospital | Headington | Oxford |
| United Kingdom | The Royal Marsden NHS | London | England |
| United Kingdom | The Christie Hospital NHS | Manchester | England |
| United Kingdom | Weston Park Hospital | Sheffield | England |
| United States | University of Chicago | Chicago | Illinois |
| United States | Cleveland Clinic | Cleveland | Ohio |
| United States | Karmanos Cancer Institute/Wayne State University | Detroit | Michigan |
| United States | Duke Univeristy Medical Center | Durham | North Carolina |
| United States | Indiana University Melvin and Bran Simon Cancer Center | Indianapolis | Indiana |
| United States | SCRI | Nashville | Tennessee |
| United States | The Vanderbilt Clinic, Henry-Joyce Cancer Center | Nashville | Tennessee |
| United States | Oregon Health & Science University | Portland | Oregon |
| United States | Washington Univ in St. Louis-School of Medicine | Saint Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Duke University | Novartis, Pfizer |
United States, Canada, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Clinical Measures of Response and PFS With Baseline and Time-dependent Levels of Biomarkers | To correlate clinical measures of response and PFS with baseline and time-dependent levels of biomarkers. These biomarkers include plasma angiokine levels, tissue immunohistochemical and genomic profiles, copy number as assessed by array-based comparative genomic hybridization (CGH), and known mutations in non-clear cell RCC | 36 months | |
| Other | Changes in Copy Number, RNA Expression, and Immunohistochemical Profiles | To evaluate in an exploratory fashion changes in copy number, RNA expression, and immunohistochemical profiles by microarray between primary non-clear cell RCC tumors and metastatic samples | 36 months | |
| Primary | Anti-tumor Activity as Measured by Median Progression Free Survival Time | The primary objective will be to compare the anti-tumor activity of everolimus and sunitinib in subjects with mRCC with non-clear cell pathology, as measured by progression-free survival (PFS) following treatment initiation according to RECIST 1.1 criteria. Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). | 24 Months | |
| Secondary | Progression Free Survival Rates | 6-, 12-, and 24-month rates of PFS in each arm will be compared for each treatment arm. Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). | 6, 12 and 24 months | |
| Secondary | PFS Expressed in Months | Progression-free survival (PFS) expressed in months as compared to an historic control (interferon-treated clear cell RCC control arm from the sunitinib phase III study). Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). | 24 months | |
| Secondary | Overall Response Rate | Defined as complete response [CR] and partial response [PR] by RECIST 1.1 criteria in each treatment arm.Overall Response Rate (ORR) = CR + PR. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. | 24 months | |
| Secondary | Percentage of Participants With Stable Disease (SD) | Percentage of participants with stable disease during treatment is defined as stable disease [SD] by RECIST 1.1 criteria as calculated in each treatment arm. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. | Baseline to 36 months | |
| Secondary | 12 Week Clinical Benefit Rate as Percentage | Rate of complete or partial response or stable disease by the RECIST 1.1 criteria lasting = 12 weeks prior to progression. Benefit rate is defined as complete response [CR] and partial response [PR] and stable disease [SD] by RECIST 1.1 criteria in each treatment arm. Benefit rate = CR + PR + SD. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. | Baseline to 36 months | |
| Secondary | Overall Survival Rates | To compare overall survival (OS) rates at 6, 12, 24, and 36 months and over time in each treatment arm. | 6, 12, 24, 36 months | |
| Secondary | Best Tumor Shrinkage as a Percentile in Each Arm | To compare the best tumor shrinkage as a percentile in each treatment arm. The percentile change at each follow up visit is calculated by measuring the percentage change in the Sum of lesion measurement from baseline. The best tumor shrinkage is lowest percentile change. A decrease is indicated by a negative percentage. | 24 months | |
| Secondary | Median Duration of Response (CR, PR, and SD) | To compare the median duration of response (CR, PR, and SD) in each treatment arm. According to RECIST 1.1, Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. | 24 months | |
| Secondary | Median OS | To compare the median OS in each treatment arm. | Up to 40 months | |
| Secondary | Time-to-new Metastatic Disease in Each Treatment Arm | To compare the time-to-new metastatic disease in each treatment arm, defined from the date of first study agent administration to the onset of a new evaluable site of disease, excluding the primary site and all sites documented at baseline | 36 months | |
| Secondary | Percentage of Participants With Adverse Events | To assess toxicities associated with everolimus or sunitinib using NCI CTC version 4.0 criteria | 24 months | |
| Secondary | Change in Quality-of-life | To compare change in quality-of-life, as measured by the FACT-KSI scale at baseline and cycle 3 day 1 per subject in each treatment arm. Functional Assessment of Cancer Therapy Kidney Symptom Index. FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms. | baseline, cycle 3 day 1 | |
| Secondary | Change in Quality-of-life | To compare change in quality-of-life, as measured by the FACT-KSI scale at baseline and cycle 6 day1 per subject in each treatment arm. Functional Assessment of Cancer Therapy Kidney Symptom Index. FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms. | baseline, cycle 6 day 1 | |
| Secondary | Change in Quality-of-life | To compare change in quality-of-life, as measured by the FACT-KSI scale at baseline and end of treatment per subject in each treatment arm. Functional Assessment of Cancer Therapy Kidney Symptom Index. FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer. The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms. | baseline, up to 40 months |